Meet Our Leaders from Around the Globe

What is a company without vision and leadership? Meet the team who’s vision and leadership has made us one of the fastest-growing CROs on the market. Click on the picture to read more about each leader.

  • Jeff Williams
    Chief Executive Officer
    Jeff Williams
    Chief Executive Officer

    Jeff co-founded Clinipace Worldwide in 2003 with the idea of building a clinical research company that would take a different approach to managing clinical trials. He wanted to build a company where technology served as the foundation of the research. At Clinipace Worldwide, technology is in our DNA with Jeff and his team successfully delivering a technology-amplified approach to conducting research resulting in strong year-over-year growth.

    Prior to founding Clinipace Worldwide, Jeff held several executive-level positions within the life sciences and software industries. As CEO of NextAudio, an early pioneer in Internet-based services, he successfully merged the company with Koz to create Mediaspan, a company that expanded to more than 200 employees and earned more than $26 million in sales.

    Additionally, Jeff was a co-founder of HealthMatics, one of the first electronic medical records (EMR) software providers, which was sold to A4 Health and later acquired by Allscripts. Prior to these technology endeavors, Jeff spent 10 years at Ciba (now Novartis) and two years at Glaxo Wellcome. During this period, he pioneered some of the earliest direct-to-consumer advertising campaigns within the industry and shared marketing-based responsibility for one of the largest Phase IV studies ever conducted at the time (more than 10,000 patients).

    Jeff served on the Board of Directors for CampbellAlliance (prior to its acquisition by InVentiv) and currently serves on the board at Cathedral Corporation, a leader in print and electronic data output services.

    Jeff has a Bachelor of Science degree in Chemistry with minors in Business Management and Biology from the University of Tampa.

    In 2007, Jeff was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.

  • Christopher Porter
    President and Chief Operating Officer
    Christopher Porter
    President and Chief Operating Officer

    Chris co-founded Clinipace Worldwide and currently serves as President and Chief Operating Officer. In this role, Chris leads corporate and business development, legal affairs, medical affairs, human resources, therapeutic leadership, regulatory and strategic development, and corporate quality assurance.

    Prior to Clinipace Worldwide, Chris served as vice president of corporate development and legal affairs for Drug Safety Alliance, Inc. (DSA). Additionally, Chris served as group manager of the Siebel Venture Group, Siebel Systems, Inc., where he was responsible for all of Siebel’s venture transactions and management of a $30M portfolio with a specific interest in life science technology opportunities. Chris joined Siebel through Siebel’s $542M acquisition of OpenSite Technologies where Chris was the original member of the business development group.

    Chris has held various other positions in the life science industry including positions in sales and marketing for Glaxo, Inc. and Quintiles Transnational, and manager of legal and business affairs for AM Pappas & Associates, one of the largest life science venture capital firms in the Southeast.

    Chris received his Juris Doctor and Master of Business Administration from the University of North Carolina at Chapel Hill in 1998. Chris also earned his Bachelor of Arts in Journalism/Advertising from UNC-CH in 1992.

    In 2008 Chris was named to the PharmaVoice 100, an annual listing of the 100 most influential people in the life sciences industry.

  • Ron Marks, PhD
    Chief Scientific Officer
    Ron Marks, PhD
    Chief Scientific Officer

    Ron co-founded Clinipace Worldwide to bring to market an eClinical trial solution that he helped develop at the University of Florida. Ron and his team in the Division of Biostatistics developed a web-based electronic clinical trial system beginning in 1996 that was used to support a 22,000 patient Phase 4 cardiology clinical trial that ran at 870 primary physician sites in 10 countries for 5 years. The University received a patent on multiple aspects of the eClinical system.

    Ron was trained as a Biostatistician. He received his MS and PhD in Statistics at the University of Florida and joined the Division of Biostatistics faculty at the J Hillis Miller Health Center at the University of Florida upon graduation. He served on the faculty for 30 years and as Director for 18 years.

    Since joining Clinipace Worldwide, Ron serves as Chief Scientific Officer and Global Director of Biostatistics.

  • Daryl Porter
    Chief Technology Officer
    Daryl Porter
    Chief Technology Officer

    Daryl leads the service engineering, product engineering, and cloud computing infrastructure teams.

    Prior to Clinipace Worldwide, Daryl spent 18 years at Oracle Corporation and held several executive level positions in both enterprise product development and enterprise support services. Daryl spent most of his career at Oracle in the Database Tools Division as a programmer, manager and vice president where he managed teams ranging from 3 to 300 with commensurate responsibilities around strategic direction, operational execution, budget, and performance.

    Daryl concluded his tenure at Oracle as the Vice President of Advanced Support Services. He was responsible for streamlining software life cycle services for global teams of over 10,000 software professionals in five countries and conducting architectural assessments for Fortune 100 Customers in the healthcare, government, financial and telecomm industries to accelerate the adoption of GRID computing and LINUX. He also managed the Oracle-Red Hat relationship as the Oracle OnDemand Service Executive. Additionally, he was an integral member of the M&A technical team tasked with conducting due diligence on Oracle’s acquisitions of Siebel and PeopleSoft.

    Daryl holds an Master of Science in Engineering (MSE) in Computer Science from Princeton University, a Bachelor of Science in Mathematical Sciences from the University of North Carolina at Chapel Hill, and is a member of Phi Beta Kappa.

  • Andree Beckerling, MD, PhD
    Chief Medical Officer and Chief Executive Officer, Europe
    Andree Beckerling, MD, PhD
    Chief Medical Officer and Chief Executive Officer, Europe

    Dr. Beckerling is Clinipace’s Chief Medical Officer and European CEO. In these roles, he reports to Jeff Williams, CEO of Clinipace Worldwide, and oversees operations within Europe and medical affairs globally. He joins Clinipace through the merger with the European CRO, Accovion, where he also acted as the Chief Executive Officer and Chief Medical Officer for 5 years. Prior to Clinipace and Accovion, Andree was the Director of Medical Scientific Affairs and Managing Director at Pierrel Research and the Managing Director and Head of Clinical Research at IFE. Andree brings more than 19 years of experience in managing and supervising  clinical trials, a profound medical and operational knowledge, as well as a broad business understanding of a highly complex market.

    Andree studied Human Medicine at Ruhr-University Bochum Medical School in Bochum, Germany and Boston University Medical Center in Boston, Massachusetts, graduated from Ruhr-University Bochum and finished his post graduate medical education as a Medical Specialist for Pharmaceutical Medicine from the Swiss Association for Pharmaceutical Medicine, Berne, Switzerland. Furthermore, Andree holds an MBA from the University of East London. He’s contributed to multiple medical articles, including Significance of Clinical Research in Germany, Treatment of Depressive Diseases with Sertraline, and Process of Measuring in Clinical Medicine: Implications of Different Definitions in Clinical Therapeutic Studies.

    Andree is a member of DGpharMed, DIA, Swiss Association for Pharmaceutical Medicine, Federal Association for Clinical Research in Pediatrics and speaks German and English.

  • Hampton Corley
    Chief Business Officer
    Hampton Corley
    Chief Business Officer

    As the Chief Business Officer, Hampton is responsible for client advocacy and ensuring client success. With twenty years of business development experience, Hampton’s central goal is to serve clients by aligning Clinipace’s operations team to shepherd the client’s asset and meet their corporate objectives. “We believe our clients need immediate engagement from the appropriate Clinipace regulatory, clinical, or statistical experts to advance to their drug or device development programs. We foster relationships with these value added events” 

    Hampton built Clinipace Worldwide’s business development organization from the ground up. Nearly 10 years later, Hampton is responsible for the global business development organization which consists of Sales, Proposals and Marketing. Prior to Clinipace, Hampton worked in business development with BioRefrence Laboratories, Ariba, Parametric Technology, and ADP. He graduated with a BBA in Finance from the University of Georgia’s Terry College of Business.

  • Ivana Waller
    Chief Business Officer, Europe
    Ivana Waller
    Chief Business Officer, Europe

    Ivana joined Clinipace Worldwide in 2013, through the merger with European CRO, Accovion, where she served as the Chief Operating Officer. Now as Clinipace’s European Chief Business Officer and Managing Director, Ivana is focused largely on client advocacy as well as overseeing the company’s European subsidiaries.

    She has been in the clinical research industry for 18 years, serving organizations in both the United States and Europe. Prior to Accovion, Ivana acted as the Vice President of Business Development at MedTrials for more than a decade.

  • Brian Travers
    Executive Director, Asia Pacific
    Brian Travers
    Executive Director, Asia Pacific

    In his current role, Brian leads Clinipace Worldwide’s regional Asia Pacific business. Prior to joining Clinipace Worldwide, Brian served as General Manager, Greater China for inVentiv Health overseeing both the clinical and commercial segments. Before joining inVentiv Health, Brian served as VP – Finance at Pharmalegacy Laboratories, a pre-clinical CRO based in Shanghai, China, where he was responsible for restructuring the organization in order to attract Series B equity investment.

    Before Pharmalegacy, he held the dual roles of Senior Manager – Finance & Administration for the International Clinical Diagnostics operations of Thermo Fisher Scientific and Regional Manager - MENA. In these roles he was responsible for overseeing the administrative activities of the operations outside of the US, as well as managing and further developing the distribution business in the Middle East and North Africa. His prior experience also includes financial roles of increasing responsibility for Thermo Fisher Scientific in the US, France, and Germany.

    Brian received his Bachelor of Science in Finance and Computer Information Systems from Indiana University – Bloomington, and is currently pursuing a Master of Science in Clinical Research Administration.

  • Barb Geiger, BSN, RN
    EVP, Global Oncology
    Barb Geiger, BSN, RN
    EVP, Global Oncology

    Barb has more than 25 years of experience in the conduct and management of Phase I-IV clinical trials and project teams. She has global expertise having run trials in more than 30 countries on six continents, and is still waiting for that trial in Antarctica!  

    Prior to founding Worldwide Clinical Research (WWCR) in 2000, she spent 10 years in leadership roles at global CROs. Additionally, Barb Spent eight years at a major pharmaceutical company and began her career in clinical research in a Phase I/II Private research unit. She is a clinical operations professional and serves our clients as an executive liaison to project teams. An oncology nurse by training, she has extensive experience in oncology and CNS drug development.

  • Cindy Venendaal
    VP, Clinical Operations, Americas
    Cindy Venendaal
    VP, Clinical Operations, Americas

    Cindy has worked in clinical operations and drug/device development across pharmaceutical, biotechnology, and clinical research organizations for the past 17 years. Her experience includes executing global clinical trials throughout North America, Asia Pacific, Latin America, and Europe. Cindy has managed Phase I-IV clinical trials across a wide variety of therapeutic areas, focusing mainly on oncology studies. She has been heavily involved in vendor selection/management, protocol development, CSR review, and support for IND and NDA submissions/approvals.

    Cindy earned her PhD in clinical science from the University of Colorado and Master of Public Health degree from the University of Northern Colorado.

  • Martin Cripps
    VP, Clinical Operations, Europe
    Martin Cripps
    VP, Clinical Operations, Europe

    Martin has worked in clinical operations and drug and device development in pharmaceutical, biotechnology, and clinical research organizations for the past 17 years. He has a thorough command of operational requirements in North America, Europe, Asia Pacific, and Africa, and has managed cross-functional and multi-cultural teams ensuring productivity and quality.

  • Ingrid Lo, MS
    VP, Clinical Operations, APAC
    Ingrid Lo, MS
    VP, Clinical Operations, APAC

    With more than 14 years of experience in clinical research at the Center of Drug Evaluation, GlaxoSmithKline, Quintiles, and Clinipace, Ingrid has acquired an in-depth knowledge of the drug development, clinical trial conduction, trial management, and regulatory perspectives. She also has experience in managing clinical operations across Phase I to Phase IV in various therapeutic areas, most extensively in vaccine development and oncology.

    Ingrid is a licensed pharmacist by training with a bachelor’s degree in pharmacy and a master’s in pharmacology.

  • Mark Shapiro, MA, MBA
    VP, Clinical Development
    Mark Shapiro, MA, MBA
    VP, Clinical Development

    A pharmacologist by training, Mark has almost 20 years of experience spanning virtually all aspects of drug development. 

    He completed an MBA at Duke University’s Fuqua School of Business. Prior to Duke, Mark did master’s and doctoral work in pharmacology and biomolecular pharmacology at the Boston University School of Medicine. He received a bachelor’s degree in chemistry at Virginia Tech.

  • Beth Garrard, PharmD
    EVP, Global Safety Operations
    Beth Garrard, PharmD
    EVP, Global Safety Operations

    A pharmacist by training, Beth has more than 20 years of experience in pharmaceutical product safety based on monitoring adverse event data for use in medical practice for both clinical investigations and post marketing. Her experience includes extensive industry-based global pharmacovigilance with both CROs and sponsor based companies with a focus in clinical research, disease management, quality, regulatory, compliance, training, risk management, benefit risk analysis, aggregate data analysis, and signal detection and management.

    Beth completed her doctorate in pharmacy at UNC’s School of Pharmacy in Chapel Hill, NC.

  • Nikolas Burlew
    VP, Regulatory and Strategic Development
    Nikolas Burlew
    VP, Regulatory and Strategic Development

    Nik is a Regulatory and Strategic Development QA professional working under GMP and GLP regulations providing auditing, training, system development, and project management services, in addition to authoring CMC sections for US and EU applications.

    Nik says: “The most important consideration a client should take when undertaking a clinical research project is that ALL drugs going into humans MUST follow good manufacturing practices. Engaging an experienced partner helps avoid not complying with GMP rules and regulations.”

  • Marie Hanley
    VP, Global Quality Services
    Marie Hanley
    VP, Global Quality Services

    Marie has worked in the clinical research industry for more than 30 years.  Over the past 12 years, she has been in global regulatory and quality assurance roles.  With a Bachelor of Science in Nursing and post-graduate work in biostatistics, she began her research career as a research nurse and study coordinator. 

    Marie is a champion of compliance and process improvement, with global regulatory inspection and audit expertise.

    Marie says: "As Steven Covey once said, 'begin with the end in mind.' The end in mind for CPWW and our Sponsors is regulatory approval for a new therapy. Although we maintain a robust internal QA audit program, you can’t audit quality in, it must be a part of the fabric of an organization from the top down and the bottom up. At Clinipace, this perspective is a key to running successful, compliant studies that pass inspections. Having this perspective allows us to challenge the way things have been done, to look for opportunities to improve, and to build reproducible quality into everything we do. This is not a static or singular process, but requires a culture of continual process improvement, staff training, and maintaining a quality system that helps deliver on that objective. Having an awareness, that your ultimate ‘customer’ is the Regulatory Inspector inspecting the study data, the patients who participate, our sites and our Sponsors, keeps our focus on what is important in the conduct of clinical research.“